U.S. Markets open in 9 hrs 10 mins

Sophiris Bio to Present at 29th Annual ROTH Conference

SAN DIEGO and VANCOUVER, British Columbia, March 6, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the 29th Annual ROTH Conference. The presentation is scheduled for Monday, March 13, 2017 at 5:00 p.m. PDT at The Ritz-Carlton, Dana Point, California.

The presentation will be webcast live and can be accessed through the Investor Relations page at www.sophiris.com. A replay of the presentation will be available on the Company's website for 90 days.

About Sophiris 
Sophiris Bio Inc. is a biopharmaceutical company developing topsalysin, a clinical-stage, targeted therapy for the treatment of urological diseases. Topsalysin has successfully completed a Phase 2a clinical trial for the treatment of localized low to intermediate risk prostate cancer. Topsalysin has also successfully completed a Phase 3 clinical study for the treatment of the symptoms of benign prostatic hyperplasia (BPH), and is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. For more information, please visit www.sophiris.com.

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Sophiris' current beliefs as well as assumptions made by and information currently available to Sophiris and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Sophiris in its public securities filings; actual events may differ materially from current expectations. Sophiris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations and Company Contact: 
Peter Slover 
Chief Financial Officer 
(858) 777-1760

Corporate Communications and Investor Relations: 
Jason Spark
Canale Communications 
Corporate Communications and IR 
(619) 849-6005
jason@canalecomm.com     

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sophiris-bio-to-present-at-29th-annual-roth-conference-300416507.html